| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
A
Agilent
|
Jun 01, 2026 | HOLD |
Strong Buy
+3.9% avg upside
32 analysts
|
$135.00
6.23% Upside
|
-2.4% |
|
CAI
Caris Life Sciences, Inc.
|
Jun 01, 2026 | HOLD |
Strong Buy
+54.5% avg upside
20 analysts
|
— | +0.2% |
|
STVN
Stevanato Group
|
Jun 01, 2026 | BUY |
Strong Buy
+54.2% avg upside
13 analysts
|
$21.00
19.81% Upside
|
-9.3% |
|
AVTR
Avantor
|
Jun 01, 2026 | SELL |
Buy
+49.6% avg upside
26 analysts
|
$7.00
27.02% Downside
|
-4.8% |
|
WST
West Pharmaceutical Services
|
Jun 01, 2026 | BUY |
Strong Buy
+6.5% avg upside
17 analysts
|
$375.00
14.30% Upside
|
+4.2% |
|
WAT
Waters
|
Jun 01, 2026 | BUY |
Strong Buy
+3.5% avg upside
30 analysts
|
$425.00
19.56% Upside
|
-5.4% |
|
TMO
Thermo Fisher
|
Jun 01, 2026 | BUY |
Strong Buy
+26.9% avg upside
38 analysts
|
$535.00
15.24% Upside
|
-6.5% |
|
RGEN
Repligen
|
Jun 01, 2026 | BUY |
Strong Buy
+28.3% avg upside
25 analysts
|
$145.00
9.85% Upside
|
-0.6% |
|
RVTY
Revvity
|
Jun 01, 2026 | HOLD |
Buy
+5.5% avg upside
23 analysts
|
— | -2.7% |
|
MTD
Mettler-Toledo
|
Jun 01, 2026 | HOLD |
Buy
+2.7% avg upside
18 analysts
|
$1180.00
3.12% Upside
|
-2.5% |
|
DHR
Danaher
|
Jun 01, 2026 | HOLD |
Strong Buy
+21.8% avg upside
45 analysts
|
— | +0.8% |
|
BRKR
Bruker
|
Jun 01, 2026 | HOLD |
Buy
-7.0% avg upside
22 analysts
|
— | -6.3% |
|
BSX
Boston Scientific
|
May 29, 2026 | HOLD |
Strong Buy
+73.0% avg upside
38 analysts
|
— | -6.2% |
|
NYXH
Nyxoah
|
May 13, 2026 | HOLD |
Strong Buy
+857.2% avg upside
12 analysts
|
— | -5.2% |
|
ABT
Abbott Laboratories
|
Apr 16, 2026 | HOLD |
Strong Buy
+31.2% avg upside
35 analysts
|
— | -7.3% |
|
EW
Edwards Lifesciences
|
Apr 01, 2026 | BUY |
Strong Buy
+11.7% avg upside
34 analysts
|
$92.00
5.31% Upside
|
+6.7% |
|
INSP
Inspire Medical Systems
|
Feb 13, 2026 | HOLD |
Buy
+98.0% avg upside
20 analysts
|
— | -29.2% |
|
MDLN
Medline
|
Jan 12, 2026 | BUY |
Strong Buy
+42.9% avg upside
26 analysts
|
$47.00
30.69% Upside
|
-15.9% |
|
MDT
Medtronic
|
Aug 25, 2025 | HOLD |
Buy
+23.7% avg upside
38 analysts
|
— | -11.8% |
|
NPCE
NeuroPace
|
Aug 14, 2025 | BUY |
Strong Buy
+13.4% avg upside
11 analysts
|
$13.00
16.93% Downside
|
+74.3% |
|
SHC
Sotera Health
|
Aug 08, 2025 | BUY |
Strong Buy
+30.3% avg upside
13 analysts
|
$17.00
7.54% Upside
|
+12.9% |
|
STE
Steris
|
Aug 08, 2025 | BUY |
Strong Buy
+22.1% avg upside
10 analysts
|
$270.00
33.35% Upside
|
-13.8% |
|
BBNX
Beta Bionics, Inc.
|
May 29, 2025 | BUY |
Strong Buy
+53.1% avg upside
13 analysts
|
$20.00
44.05% Upside
|
-5.4% |
|
LIVN
LivaNova
|
May 19, 2025 | BUY |
Strong Buy
+0.2% avg upside
14 analysts
|
$60.00
23.59% Downside
|
+59.2% |
|
PODD
Insulet
|
May 12, 2025 | BUY |
Strong Buy
+79.3% avg upside
32 analysts
|
$350.00
140.16% Upside
|
-52.7% |
|
KMTS
Kestra Medical Technologies Ltd.
|
Mar 31, 2025 | BUY |
Strong Buy
+37.5% avg upside
7 analysts
|
$29.00
45.56% Upside
|
-17.2% |
|
RMD
Resmed
|
Sep 17, 2024 | SELL |
Buy
+25.4% avg upside
27 analysts
|
$180.00
4.67% Downside
|
+21.7% |
|
ZBH
Zimmer Biomet Holdings
|
Sep 09, 2024 | HOLD |
Buy
+27.6% avg upside
37 analysts
|
— | -13.9% |
|
SYK
Stryker
|
Sep 09, 2024 | BUY |
Strong Buy
+24.1% avg upside
36 analysts
|
$405.00
31.53% Upside
|
-14.9% |
|
IRTC
Irhythm Technologies
|
Jun 19, 2024 | BUY |
Strong Buy
+62.0% avg upside
19 analysts
|
$115.00
9.92% Upside
|
+14.6% |
|
EMBC
Embecta Corporation
|
Oct 19, 2023 | HOLD |
Sell
+146.5% avg upside
5 analysts
|
— | -3.8% |
|
DXCM
Dexcom
|
Jul 28, 2023 | BUY |
Strong Buy
+38.8% avg upside
32 analysts
|
$140.00
93.23% Upside
|
-32.4% |
|
TFX
Teleflex
|
Apr 25, 2023 | HOLD |
Buy
+42.3% avg upside
19 analysts
|
— | -48.9% |
|
TNDM
Tandem Diabetes Care
|
Jan 26, 2023 | HOLD |
Buy
+115.3% avg upside
29 analysts
|
— | -7.3% |
|
ISRG
Intuitive Surgical
|
Apr 05, 2022 | HOLD |
Strong Buy
+29.5% avg upside
36 analysts
|
$315.00
22.61% Downside
|
+31.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.